http://www.jcps.ac.cn

Journal of Chinese Pharmaceutical Sciences ›› 2018, Vol. 27 ›› Issue (1): 59-63.DOI: 10.5246/jcps.2018.01.007

• Drug administration and clinical pharmacy column • Previous Articles     Next Articles

Clinical development of tumor necrosis factor-alpha inhibitors for ankylosing spondylitis

Zhou Linguang1,2, Jiang Bin2*   

  1. 1. Department of Pharmacy, Peking University International Hospital, Beijing 102206, China
    2. Department of Administrative and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
  • Received:2017-03-24 Revised:2017-08-19 Online:2018-02-28 Published:2017-11-15
  • Contact: Tel.: +86-13601100121, E-mail: zhoulinguang@pkuih.edu.cn

Abstract:

There is no radical cure for ankylosing spondylitis, a chronic inflammation in joint, till now. Tumor necrosis factor-alpha (TNF-α) inhibitors can block the cascade in inflammatory chain and improve clinical symptom. Among these biological agents, three of them are marketed in China: etanercept, infliximab and adalimumab. Some of the research progresses between 2014 and 2016 are summarized including treatment application, side effects of drugs, and comprehensive research of TNF-α inhibitors. 

Key words: Ankylosing spondylitis, TNF-α, Etanercept, Infliximab, Adalimumab

CLC Number: 

Supporting: